Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Well-Differentiated Neuroendocrine Carcinoma”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Early research (Phase 1)WithdrawnNCT02831179
What this trial is testing

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Who this might be right for
Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMerkel Cell Carcinoma+26 more
Vanderbilt-Ingram Cancer Center
Not applicableStudy completedNCT02592356
What this trial is testing

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaMalignant Adrenal Gland PheochromocytomaMalignant Paraganglioma+1 more
M.D. Anderson Cancer Center 23
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03879694
What this trial is testing

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Who this might be right for
Lung Atypical Carcinoid TumorLung Typical Carcinoid TumorMetastatic Pancreatic Neuroendocrine Tumor
Roswell Park Cancer Institute 19
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Testing effectiveness (Phase 2)Study completedNCT00121628
What this trial is testing

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer
Amgen 184
Not applicableStudy completedNCT03616431
What this trial is testing

Pancreatic Cancer Dietary Assessment Study

Who this might be right for
Pancreatic NeoplasmPancreas AdenocarcinomaWell-Differentiated Neuroendocrine Carcinoma+1 more
The Christie NHS Foundation Trust 112
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Not applicableLooking for participantsNCT04464122
What this trial is testing

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1+2 more
University of Roma La Sapienza 60
Not applicableLooking for participantsNCT07259304
What this trial is testing

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+97 more
University of Southern California 250
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT00869050
What this trial is testing

Capecitabine and Temozolomide for Neuroendocrine Cancers

Who this might be right for
Neuroendocrine Tumors
Columbia University 41
Testing effectiveness (Phase 2)Looking for participantsNCT07357623
What this trial is testing

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Who this might be right for
Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital 96
Testing effectiveness (Phase 2)Study completedNCT00953394
What this trial is testing

5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University of Turin, Italy 29
Not applicableUnknownNCT06400654
What this trial is testing

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Who this might be right for
Neuroendocrine Carcinoma
European Institute of Oncology 100
Testing effectiveness (Phase 2)Study completedNCT00781911
What this trial is testing

Cixutumumab (IMC-A12) in Islet Cell Cancer

Who this might be right for
CarcinomaNeuroendocrine Tumors
Eli Lilly and Company 43
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Testing effectiveness (Phase 2)UnknownNCT01118065
What this trial is testing

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Leiden University Medical Center 42
Post-approval studies (Phase 4)Study completedNCT01525550
What this trial is testing

The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Who this might be right for
Well-differentiated Pancreatic Neuroendocrine Tumor
Pfizer 106
Load More Results
189
116